Balchem Corporation

Balchem Corporation (BCPC) Stock Analysis

$170.530

+0.068 (+0.04%)At close

Loading chart…
High
173.080
Open
172.045
VWAP
171.32
Volume
349.11K
Mkt Cap
4.92B
Low
170.355
Amount
59.81M
EV/EBITDA, TTM
18.55

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

balchem.com

AI analysis of Balchem Corporation (BCPC)

Buy

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

Valuation Metrics

The current forward P/E ratio for Balchem Corporation (BCPC) is 29.33, compared to its 5-year average forward P/E of 32.66.

Forward P/E

Fair
5Y Average P/E
32.66
Current P/E
29.33
Overvalued
36.02
Undervalued
29.30

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
20.56
Current EV/EBITDA
18.55
Overvalued
22.65
Undervalued
18.47

Forward P/S

Fair
5Y Average P/S
4.78
Current P/S
4.52
Overvalued
5.36
Undervalued
4.20

Alphio AI Price Scenarios for BCPC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BCPC

$162.17

Scenario price

B

Base

Base · 50%BCPC

$159.96

Scenario price

B

Bear

Bear · 25%BCPC

$150.29

Scenario price

Whales holding BCPC

S

Salem Investment Counselors, Inc.

+ HoldingBCPC

+6.48%

3M Return

W

Wasatch Advisors LP

+ HoldingBCPC

+0.81%

3M Return

N

Nationwide Fund Advisors

+ HoldingBCPC

+0.38%

3M Return

Events Timeline

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

News

BCPC FAQ — answered by Alphio AI

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading